US Bancorp
JANX icon

US Bancorp’s Janux Therapeutics JANX Stock Holding History

US Bancorp’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1K Buy
1,636
+1,189
+266% +$17.2K ﹤0.01% 3109
2026
Q1 		$6.21K Buy
+447
New +$6.13K ﹤0.01% 3512
2025
Q4 		– Sell
-1,774
Closed -$43.4K – 4130
2025
Q3 		$43.4K Buy
1,774
+75
+4% +$1.83K ﹤0.01% 2742
2025
Q2 		$39.2K Sell
1,699
-28
-2% -$738 ﹤0.01% 2893
2025
Q1 		$46.6K Buy
1,727
+1,658
+2,403% +$62.5K ﹤0.01% 2785
2024
Q4 		$3.69K Sell
69
-19
-22% -$1K ﹤0.01% 3727
2024
Q3 		$4K Sell
88
-121
-58% -$5.26K ﹤0.01% 3641
2024
Q2 		$8.76K Buy
209
+195
+1,393% +$9.16K ﹤0.01% 3358
2024
Q1 		$527 Sell
14
-76
-84% -$1.66K ﹤0.01% 3858
2023
Q4 		$966 Hold
90
– – ﹤0.01% 3805
2023
Q3 		$907 Hold
90
– – ﹤0.01% 3784
2023
Q2 		$1.07K Hold
90
– – ﹤0.01% 3798
2023
Q1 		$1.09K Buy
+90
New +$1.5K ﹤0.01% 3856
2021
Q3 		– Sell
-7
Closed – – 4126
2021
Q2 		$0 Buy
+7
New +$156 ﹤0.01% 4037

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

US Bancorp's JANX Position: Q2 2026 in Review

US Bancorp increased its Janux Therapeutics (JANX) stake by 266% in Q2 2026, buying an estimated $17.2K and bringing the position to 1,636 shares worth $25.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3109.

US Bancorp first reported a position in JANX in Q2 2021 and has held it in 14 quarters since. The position peaked at $46.6K in Q1 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • US Bancorp held 1,636 shares of Janux Therapeutics worth $25.1K as of Q2 2026.
  • US Bancorp bought 1,189 Janux Therapeutics shares in Q2 2026, an estimated $17.2K.
  • Janux Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3109 holding.
  • US Bancorp first reported a position in Janux Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • US Bancorp's Janux Therapeutics position peaked at $46.6K in Q1 2025.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.